Tofacitinib (CP-690,550) in Combination with Traditional Disease-Modifying Anti-Rheumatic Drugs: Phase 3 Study Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis and An Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs. 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP) Strand, V., Kremer, J. M., Li, Z. G., Hall, S., Fleischmann, R. M., Genovese, M. C., Martin-Mola, E., Isaacs, J., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S. H., Koncz, T., Riese, R., Bradley, J. D. WILEY-BLACKWELL. 2011: S1032–S1032

View details for Web of Science ID 000297621503206